“…In human patients with a high cardiologic mechanical index and systolic triggering, CEUS can elicit premature ventricular contractions. Although none of the case animals that were administered the perflutren protein type A microsphere contrast agent in the present study developed adverse events, the proportion of study animals that received that contrast agent was small, and on the basis of results of the other study, 23 administration of the perflutren protein type A microsphere contrast agent is not recommended in animals. At the cellular level, microbubble contrast agents cause microvascular rupture, which can be useful for delivery of the agent to particular parts of the body that are otherwise difficult to access (ie, across the blood-brain barrier); however, damage to endothelial cells caused by the contrast agents was not permanent.…”